Les Kjosness, President & CEO, is pleased to announce the ‘Company’ on March 30, 2015 completed its first AGM as Marapharm Ventures Inc. The Notice of Meeting, Proxy, Information Circular and Financial Statement Request Card were mailed to the shareholders of the Company in accordance with the British Columbia Business Corporations Act. We had a thirty three percent (33%) response from our shareholders. All of shareholders had a one hundred percent (100%) positive vote for the Management team as recommended in the proxy.
The number of Directors was set at three, with the re-election of Les Kjosness, Corey Klassen and Brian Peterson. Saturna Group, Chartered Accountants, was appointed as our auditors for the ensuing year. The ten percent (10%) Stock Option Plan was accepted and ratified subject to regulatory approval.
On behalf of the Board
President & Director
The CSE has neither approved nor disapproved the accuracy of this news release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Companies’ documents filed from time to time on SEDAR (www.sedar.com). Readers are cautioned not to place undue reliance on these forward – looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward – looking statements, whether as a result of new information, future events or otherwise.